


PHARMACEUTICAL 2023

Qualigen Therapeutics Inc. Rank 331 of 446







PHARMACEUTICAL 2023

Qualigen Therapeutics Inc. Rank 331 of 446



The relative strengths and weaknesses of Qualigen Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Qualigen Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 69% points. The greatest weakness of Qualigen Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is -32%, being 75% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	10,821
Cost of Goods Sold	0
Intangible Assets	6,471
Liabilities, Current	8,608
Liabilities, Non-Current	1,302
Other Assets	1,447
Other Compr. Net Income	2,445
Other Expenses	9,227
Other Liabilities	407
Other Net Income	882
Other Revenues	4,984
Property and Equipment	345
Research and Development	6,837
Selling, General and Administrative Expense	10,836

Output Variable	Value in 1000 USD
Assets	19,083
Liabilities	10,317
Expenses	26,900
Revenues	4,984
Stockholders Equity	8,767
Net Income	-21,035
Comprehensive Net Income	-19,812
Economic Capital Ratio	-32%

